How pharma, under attack from all sides, keeps winning in Washington

16 July 2019 - It does not seem to matter how angrily President Trump tweets, how pointedly House Speaker Nancy ...

Read more →

With eyes on Gilead, law makers want details on how HHS reviews possible patent infringement

18 June 2019 - A pair of law makers has asked the Government Accountability Office to review how the U.S. ...

Read more →

They were supposed to talk about the patent system driving up drug prices. But most lawmakers got distracted by small tweaks.

7 May 2019 - If there was any hope that Congress might overhaul the way this country doles out the ...

Read more →

Pharmaceutical protections in U.S. trade deals — what do Americans get in return?

1 May 2019 - U.S. trade deals increasingly include terms affecting the approval process and availability of medicines.  ...

Read more →

Drug company protections are latest stumbling block for NAFTA rewrite

21 March 2019 - President Trump’s ability to get his revised North American Free Trade Agreement through Congress may hinge ...

Read more →

‘One-and-done’ for new drugs could cut patent thickets and boost generic competition

11 February 2019 - In a perfect world, the system for conveying medications from their makers to patients should be ...

Read more →

Patent abuse is driving up drug prices. Just look at Lantus.

7 December 2018 -  A rare point of consensus following the midterm elections is that Americans are adamant about lowering ...

Read more →

AbbVie announces Humira (adalimumab) global patent license with Pfizer

30 November 2018 - AbbVie announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product.  ...

Read more →

AbbVie announces Humira (adalimumab) global patent license with Momenta

6 November 2018 - AbbVie announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product.  ...

Read more →

Competition watchdog’s appeal over Pfizer ruling dismissed

19 October 2018 - The High Court has dismissed the ACCC’s application to appeal a decision on whether Pfizer’s local ...

Read more →

AbbVie announces global resolution of Humira (adalimumab) patent disputes with Fresenius Kabi

18 October 2018 - Agreements provide non-exclusive license to Fresenius Kabi for Humira related intellectual property in the U.S. effective 30 ...

Read more →

Drug price transparency won’t end the patent games

17 October 2018 - Just look at Humira, which is keeping its U.S. monopoly as generics hit the European market. ...

Read more →

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

11 October 2018 - Resolution paves way for 2018 launch in key European markets and secures US market entry planned in ...

Read more →

Age-related macular degeneration: treatment at what cost?

29 September 2018 - An estimated 8·4 million people worldwide have moderate to severe vision loss caused by age-related macular degeneration. ...

Read more →

NHS wins legal battle against drugs giants over saving millions with cheaper medicine

21 September 2018 - The NHS has won a landmark battle against drug giants paving the way for the health ...

Read more →